Patents Assigned to DENALI THERAPEUTICS, INC.
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240018253
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 18, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Fusion proteins comprising enzyme replacement therapy enzymes
    Patent number: 11866742
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: January 9, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anastasia Henry, Mihalis S. Kariolis, Cathal S. Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman
  • Compounds, compositions and methods
    Patent number: 11851433
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • FUSION PROTEINS COMPRISING PROGRANULIN
    Publication number: 20230406898
    Abstract: Provided herein are fusion proteins that comprise progranulin and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: April 12, 2023
    Publication date: December 21, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gilbert Di Paolo, Todd P. Logan, Kathryn M. Monroe, Ankita Srivastava, Bettina Van Lengerich
  • Substituted pyrimidines as LRKK2 inhibitors
    Patent number: 11840529
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 12, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
    Patent number: 11834438
    Abstract: The present disclosure relates to methods of making LRRK2-inhibiting, pyrimidinyl-4-aminopyrazole compounds and intermediates of formulae I and IV: The compounds are useful as LRRK2 inhibitors in the treatment of LRRK2 mediated diseases, and as intermediates for their manufacture.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Travis Remarchuk, Anantha Sudhakar
  • Compounds, compositions, and methods
    Patent number: 11834439
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINS
    Publication number: 20230381286
    Abstract: Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
    Type: Application
    Filed: February 8, 2023
    Publication date: November 30, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
  • Engineered transferrin receptor binding polypeptides
    Patent number: 11795232
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 24, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Anti-BACE1 antibodies and methods of use thereof
    Patent number: 11773185
    Abstract: In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-? formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: October 3, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer A. Getz, Rinkan Shukla, Adam P. Silverman, Yin Zhang, Joy Yu Zuchero
  • PROGRANULIN VARIANTS
    Publication number: 20230265137
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 24, 2023
    Publication date: August 24, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • Engineered polypeptides
    Patent number: 11732023
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 22, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20230235072
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 15, 2022
    Publication date: July 27, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230227436
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 20, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS
    Publication number: 20230192887
    Abstract: In one aspect, bispecific proteins having the ability to specifically bind to both subdomain II of human HER2 and subdomain IV of human HER2 are provided. In another aspect, methods of treating a cancer or treating brain metastasis of a cancer using a bispecific protein that specifically binds to subdomain II and subdomain IV of human HER2 are provided.
    Type: Application
    Filed: August 11, 2022
    Publication date: June 22, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gunasekaran Kannan, Do Jin Kim, Wanda Kwan, Raymond Ka Hang Tong
  • Phospho-Rab antibodies, assays and methods of use thereof
    Patent number: 11661461
    Abstract: In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR (SEQ ID NO:123). In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY (SEQ ID NO:125). Methods and materials for detecting LRRK2 and Rab protein are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 30, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Jason C. Dugas, Anastasia Henry, Sarah Huntwork-Rodriguez, Michael T. Maloney, Nathan Moerke, Ella Negrou, Xiang Wang
  • Progranulin variants
    Patent number: 11643446
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: May 9, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • METHODS FOR TREATING DYSREGULATED LIPID METABOLISM
    Publication number: 20230132366
    Abstract: Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
    Type: Application
    Filed: November 26, 2019
    Publication date: April 27, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH
  • Transferrin receptor transgenic models
    Patent number: 11612150
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 28, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero